Study S000746

A Multicenter Randomized Controlled Trial Evaluating AI-Assisted Intensive Lifestyle Intervention Versus Tirzepatide for Glycemic and Weight Management in Patients With Obesity and Newly Diagnosed Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT07697391
Acronym: AI-LIFE-T2D-OB
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 285
Start: 2026-07-20
Primary completion: 2027-10-31
Lead sponsor: The First Affiliated Hospital of Anhui Medical University
Conditions: Obesity; Diabetes Mellitus, Type 2
Interventions: BEHAVIORAL:AI-Assisted Intensive Lifestyle Intervention; DRUG:Tirzepatide; BEHAVIORAL:Standard Lifestyle Management
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:MR-34-26-044995

Registered primary outcomes

Percent Change in Body Weight From Baseline to Week 52 [Baseline to Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.